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Abstract Parkinson’s disease (PD), the secondmost common
progressive neurodegenerative disorder, was long believed to
be a non-genetic sporadic syndrome. Today, only a small per-
centage of PD cases with genetic inheritance patterns are
known, often complicated by reduced penetrance and variable
expressivity. The few well-characterized Mendelian genes,
together with a number of risk factors, contribute to the major
sporadic forms of the disease, thus delineating an intricate
genetic profile at the basis of this debilitating and incurable
condition. Along with single nucleotide changes, gene-dosage
abnormalities and copy number variations (CNVs) have
emerged as significant disease-causing mutations in PD.
However, due to their size variability and to the quantitative
nature of the assay, CNV genotyping is particularly challeng-
ing. For this reason, innovative high-throughput platforms and
bioinformatics algorithms are increasingly replacing classical
CNV detection methods. Here, we report the design strategy,
development, validation and implementation ofNeuroArray, a
customized exon-centric high-resolution array-based compar-
ative genomic hybridization (aCGH) tailored to detect single/
multi-exon deletions and duplications in a large panel of PD-
related genes. This targeted design allows for a focused eval-
uation of structural imbalances in clinically relevant PD genes,
combining exon-level resolution with genome-wide coverage.
The NeuroArray platform may offer new insights in elucidat-
ing inherited potential or de novo structural alterations in PD
patients and investigating new candidate genes.
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Parkinson’s disease (PD) is a progressive debilitating
movement disorder that affects approximately 1 % of the
population older than 65 years of age worldwide [1].
Clinically, most patients present resting tremor, bradyki-
nesia, stiffness of movement and postural instability.
These major symptoms derive from the profound and se-
lective loss of dopaminergic neurons in the substantia
nigra pars compacta (SNc), coupled with the accumula-
tion of eosinophilic intracytoplasmic aggregates termed
Lewy bodies (LBs) [1]. Like other complex diseases, PD
is believed to be a multifactorial syndrome, resulting from
an elaborate interplay of numerous elements (genes, sus-
ceptibility alleles, environmental exposures and gene-
environment interactions), and its molecular aetiology re-
mains incompletely understood [2].
In recent years, the intensive efforts of the scientific
community and the significant and rapid advancement of
biotechnologies have fuelled several steps towards the
elucidation of the genetic components of PD. Genome-
wide linkage scans and exome sequencing of well-
characterized PD families have been successful in dis-
covering disease-causing mutations in dominant (SNCA,
LRRK2, VPS35 and the recent TMEM230), recessive
(PARK2, PINK1, DJ1, DNAJC6) [2–4] and X-linked
(RAB39B) PD genes [5, 6]. Other genes, such as
CHCHD2 and EIF4G1, are associated with familial PD
inheritance but still require independent confirmations [7,
8]. Moreover, a set of genes related to atypical parkinso-
nian forms is known and includes ATP13A2, whose mu-
tations cause the Kufor-Rakeb syndrome (PARK9) [9].
Despite the existence of these rare Mendelian monogenic
forms, it is now clear that PD is a genetically heteroge-
neous and most likely complex disorder. This complexity
is underlined by the notion that we are currently aware
of dozens of loci, genes and risk factors that seem to
contribute to PD [2, 10]. These genes are involved in
numerous cellular pathways, such as the ubiquitin-
proteasome system, synaptic transmission, autophagy, ly-
sosomal autophagy, endosomal trafficking, mitochondrial
metabolism, apoptosis and inflammatory mechanisms, all
of which are generally implicated in neuronal cell death
[11].
While the major pathogenicmutations are single nucleotide
polymorphisms (SNPs) in the coding regions of PD-linked
genes, the contribution of other types of DNA molecular de-
fects (e.g. structural chromosome abnormalities such as
CNVs) to the genomic architecture is less emphasized but
equally significant [12, 13]. CNVs are unbalanced rearrange-
ments larger than 50 bp and arise from genomic instability
[12]. They are recognized as critical elements for the develop-
ment and maintenance of the nervous system and appear to
contribute to hereditable or sporadic neurological diseases,
including neuropathies, epilepsy, autistic syndromes, psychi-
atric illnesses and neurodegenerative diseases, such as PD
[14–16]. In this regard, several CNVs have been reported in
PD patients, including specific pathogenic anomalies mapped
in PD loci or involving candidate PD-related genes [17]. To
mention the most recurrent, SNCA copy-number gains have
been proven to play a major role in the disease severity of
PARK1, while PARK2 homozygous or compound heterozy-
gous exon copy number changes are very common among the
early-onset cases, rendering the gene-dosage assay essential in
mutational screening.
Currently, the detection of CNVs and gene dosage
imbalances mainly relies on traditional methodological
approaches (karyotyping and PCR-based approaches
such as quantitative PCR and multiple ligation probe
analysis). However, these methodologies bear objective
limits: they are time-consuming and labour-intensive,
require multiple phase steps and severe equipment costs
and, above all, do not provide a complete genomic
overview of structural imbalances at sufficiently high
resolution. The development of the array-based compar-
ative genomic hybridization (aCGH) technology has dra-
matically improved and catalysed the detection and
characterization of multiple CNVs, offering high repro-
ducibility, high resolution and scalability for complete
genome-wide mapping of imbalances [18]. The aCGH
technique has been refined to the most advanced
aCGH plus SNP edition, a widely used array able to
simultaneously perform SNP genotyping and CNV de-
tection. This methodology shows higher sensitivity for
the detection of low-level mosaic aneuploidies and chi-
merism and offers the ability to detect loss of heterozy-
gosity, but it has a limited ability to detect single-exon
CNVs due to the distribution of SNPs across the ge-
nome. For this reason, several customized aCGHs suit-
ably designed to focus on specific clinically relevant
chromosomal locations have been developed and are
already applied to different human diseases, including
neuromuscular diseases, cancer, autism, epilepsy, multi-
ple sclerosis, mitochondrial and metabolic disorders
[19–24].
In this study, we developed a customized exon-centric
aCGH (hereafter called NeuroArray), tailored to detect
single/multi-exon deletions and duplications in a large panel
of PD-related genes. We will first report the design strategy
and the applied analysis methods. Then, we will show two
representative PD cases tested on NeuroArray. Our findings
show the advantages of the NeuroArray platform in terms of
results, time and costs, as well as for the discovery of new
potential genetic biomarkers underlying the pathogenic mech-
anisms of PD and commonly shared genetic signatures with
other neurological diseases.
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Materials and methods
Gene selection and aCGH design strategy
To build the customized NeuroArray aCGH platform, we
aimed to obtain a high-density probe coverage in the coding
region of clinically relevant genes associated with PD. Gene
selection relied on our expertise in the clinic, genetics and
literature data and has been extended to the entire currently
known sets of genes collected in PDGene (http://www.
pdgene.org/) [25]. The list of selected genes embraces
disease-causing genes, known and putative risk factors and
other genetic regions affected by different types of mutations.
To perform a differential diagnosis, we also included genes
related to other neurological conditions (see Supplementary
Information and Supplementary Tables).
The array design was carried out by using the web-based
Agilent SureDesign Software (Agilent Technologies, Santa
Clara, CA), a web application that allows one to define re-
gions of interest and select the Bbest-performing^ probes from
the High-Density (HD) Agilent probe library. Candidate
probes were scored and filtered using bioinformatics predic-
tion criteria for probe sensitivity, specificity and responsive-
ness under appropriate conditions. We also selected a limited
number of probes by genomic tiling to cover regions inade-
quately represented in the Agilent database. All probes had
similar characteristics: isothermal probes, with melting tem-
perature (Tm) of 80 °C and probe length of approximately 60-
mers, in accordance with the manufacturer’s specifications.
Further details about the design method, the number of genes
and exons, the median probe spacing and other characteristics
of NeuroArray are summarized in Table 1, Supplementary
Information and Supplementary Table 1.
Clinical sample selection
To validate the NeuroArray, we selected DNA samples from
individuals suffering from PD or other neurological disorders
and previously subjected to gene dosage through multiplex
ligation-dependent probe amplification (MLPA), quantitative
real-time polymerase chain reaction (qPCR) or other commer-
cially available whole-genome aCGH. Moreover, DNA sam-
ples of patients with PD phenotypes but an incomplete molec-
ular diagnosis were referred for NeuroArray molecular cyto-
genetic testing. Informed consent was obtained for the use of
DNA samples and for the access to medical records for re-
search purposes.
Microarray experiment and data analysis
Genomic DNA was extracted from peripheral blood lympho-
cytes using the EZ1DNABlood extraction kit (Qiagen, Hilden,
Germany) by the BioRobot EZ1 following the manufacturer’s
recommendations (Qiagen, Hilden, Germany). Highly concen-
trated DNAwas checked for quality using the NanoDrop spec-
trophotometer (Thermo Scientific, Wilmington, DE). Array ex-
periments were performed as recommended by the manufactur-
er (Agilent Technologies, Santa Clara, CA), and data were ex-
tracted using Feature Extraction software (Agilent
Technologies, Santa Clara, CA). After the quality control
check, data visualization and analysis were performed with
CytoGenomics software v. 3.0.6.6. (Agilent Technologies,
Santa Clara, CA) using both ADM-2 and ADM-1 algorithms.
Moreover, we took into account a single-probe analysis to in-
clude putative exonic variants. Significant single exonic probe
signals were clustered for pathologies according to their loca-
tion on causative or susceptibility genes through a homemade
script on R-platform [26]. Full details on microarray experi-
ments and data analysis are available in the Supplementary
Information.
Validation
Ad hoc qPCR assays were performed to validate genomic
imbalances detected by the NeuroArray as previously de-
scribed [27]. Primers flanking the putative exonic imbalances
were designed using the Primer-BLAST tool (http://www.
ncbi.nlm.nih.gov/tools/primer-blast/). Each qPCR assay was
performed in triplicate using the LightCycler 1.5 (Roche
Diagnostics, Germany). The relative quantification was
measured using the ΔΔCt method, which requires a healthy
control sample (diploid) as a calibrator in all amplifications
Table 1 Main characteristics of the customized PD panel
Customized PD panel design
Total genes 505
Total exonic targets 6826
Target coverage 94 %
Total target/exon size 1935 Mbp
Total probes (1–2 probes per exon) 11,161
Total unique probes from HD database 10,411
Total unique probes by genomic tiling 750
Median probe spacing 391 bp
Mean target size 323 bp
Uncovered targets 431
The table lists the total number of selected genes and exon targets, the
mean exon size, the number of probes, the median probe spacing and the
total coverage of the customized design for CNV detection in PD. The
array design was performed through the Agilent SureDesign software
(https://earray.chem.agilent.com/suredesign/). The majority of probes
have been scored and filtered from the High-Density (HD) Agilent probe
library. A limited number of probes have been designedwith theGenomic
Tiling option to cover regions inadequately represented in the Agilent
database. All probes have been chosen with similar characteristics: iso-
thermal probes, with melting temperature (Tm) of 80 °C and probe length
of 60-mers
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[28]. As a calibrator control, we used the same DNA reference
hybridized in the NeuroArray experiments. A control gene,
checked as normal double copies on NeuroArray, was used
as a reference for normalization.We considered aΔΔCt value
≤0.6 as a loss, included from 0.8 to 1.2 as normal diploid, and
≥1.4 as a gain. PCR products were visualized by agarose gel
electrophoresis.
Results
aCGH design on a targeted PD gene panel
To perform a comprehensive analysis of CNVs in PD-related
genes, we developed a focused customized oligonucleotide
aCGH design targeting 505 genes and 6826 exonic regions
linked to PD. Overall, 11,161 probes with a median probe
spacing of 391 bp were enriched in the coding regions of these
genes (Table 1). The majority of targeted genes map on chro-
mosome 1, while lower numbers are distributed among the
other chromosomes (Fig. 1).
The tightly restricted criteria used for the array customiza-
tion have allowed a higher exonic probe enrichment on select-
ed gene panels, overcoming the resolution of commercially
available genome-wide CGH array platforms. Overall, 94 %
of the total exon targets are covered by at least one probe in the
NeuroArray design (Table 1), while other commercially avail-
able aCGH platforms provide a lower probe coverage of the
same selected exonic regions. For example, the Agilent
SurePrint G3 Human CGH Microarray 8 × 60K slide format
covers our selected regions by 8.2 %, while the highest-
resolution 1 × 1M array provides 25 % of our target coverage.
A representative illustration is reported in Fig. 2 and focuses
on PINK1 (RefSeq acc. no. NM_032409.2).
To perform an accurate differential analysis between PD
patients and other neurological phenotypes, we also included
genes related to other neurological disorders (Supplementary
Information and Supplementary Tables). Specifically, 160 of
the 505 PD-related genes were linked to other neurological
conditions (Fig. 1).
CNVs of PD-related genes detected
through the NeuroArray platform
NeuroArray was able to confirm copy number changes previ-
ously characterized by other methodological strategies and
revealed new interesting genomic imbalances. In the follow-
ing sections, we will show two representative examples of
NeuroArray tests obtained by using genomic DNA samples
of PD patients. Further CNVs were observed in other neuro-
logical disease-related panels and were validated by qPCR
(data not shown).
Application of an integrated ADM-1 and ADM-2
algorithm-based data analysis to improve CNV calling
The DNA sample of patient no. 1 was referred to our labora-
tory for molecular testing of PARK2, PINK1 and DJ1, to con-
firm the clinical diagnosis of familial recessive early-onset
PD. Mutation analysis showed a heterozygous C1305T single
Fig. 1 Distribution of selected PD genes on the human genome and
overlap with other neurological diseases. a Graphical representation
showing the number of clinically relevant genes for chromosomes
included in the customized PD panel. The total number of selected
genes is 505, mostly enclosed in chromosome 1. Chromosome Y does
not include PD-related genes. b The PD panel globally targets 505 PD-
related genes. Of these, 345 are specific for PD, while 160 are in common
with other neurological diseases. These latter ones can be useful to study
the potential overlapping genetic signatures among different neurological
conditions and to better define the genotype/phenotype correlations
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nucleotide substitution in the coding region of PARK2.
NeuroArray (with the ADM-1 algorithm) revealed 10 differ-
ent CNVs, overall composed of 6 gains and 4 losses (Table 2).
Four of them included genes previously linked to PD [29–32],
while the others overlapped with genes related to other neu-
rological conditions [33–42] (Table 2).
The most interesting findings regarded two principal dos-
age anomalies: (i) the gain of a 1442-kb region on chromo-
some 1, which encompasses PARK7, and (ii) the loss of the
NSF (N-ethylmaleimide-sensitive factor) gene on chromo-
some 17 (Fig. 3a, b). Mutations in PARK7 comprehensively
account for ∼1 % of the early-onset familial cases [1], and its
copy number changes have been previously observed in PD
patients [43, 44]. NSF is involved in vesicular trafficking,
membrane fusion and synaptic neurotransmission, and its ge-
netic alterations (both SNPs and deletion) have been previous-
ly reported in PD patients [31, 45]. Validations of these geno-
mic rearrangements were performed with qPCR assays, suit-
ably designed to target PARK7 exon 1 and NSF exon 11. Both
assays confirmed the CNVs with 100 % concordance and
confirmed the heterozygous gain/loss (Fig. 3c). Primer se-
quences and PCR conditions are available upon request.
It should be highlighted that the default analysis with the
ADM-2 algorithm revealed the loss of only the NSF gene. If
this method were the only one applied, other relevant real
CNVs (like the PARK7 gain, later confirmed by qPCR) would
have been lost. On the other hand, the analysis with ADM-2
allowed for the filtering of possible false-positive CNVs
within the ADM-1 analysis. It appears important, therefore,
to integrate data from both CNV calling algorithms in order to
provide a more accurate data analysis and, consequently, en-
sure a more effective quality assessment and experimental
validation.
Detection of single-exon copy number changes
by NeuroArray
Although some authors have outlined the evidence that a sig-
nificant proportion of single probe intervals represents real
events [46], in aCGH studies, it is often recommended to
report only intervals detected by three or more consecutive
probes. Due to this approach, deletions or duplications below
certain size cut-offs are usually ignored in the aCGH reports
and not reported. However, these genomic alterations (detect-
ed by less than three probes) have been demonstrated to be
definitively crucial for particular clinical diagnoses [47].
Along this line, we applied a single probe analysis to reveal
short genomic imbalances in the exonic regions of strongly
linked causative genes. The utility of this approach on
NeuroArray data analysis is shown in the following case.
Patient no. 2 was a sporadic PD patient, carrying a hetero-
zygous deletion of two adjacent exons (4 and 5) of the PARK2
gene. This deletion was previously revealed by an MLPA
assay (SALSA MLPA Kit P051/P052 Parkinson; MRC-
Holland). The NeuroArray test was able to detect and confirm
the deletion of exon 5 through two consecutive probes (Fig. 4)
Fig. 2 Oligonucleotide probe distribution on PINK1 in different
commercially available whole-genome aCGH platforms and
NeuroArray. a The human PINK1 gene is located on chromosome 1
(cytoband p36.12), spanning approximately 18 kb of genomic DNA. b
This gene produces an mRNA transcript encompassing eight exonic
regions (NCBI accession number NM_032409.2). Exons are
represented in the figure by black boxes and are numbered
consecutively. The gray line represents intronic regions. c Distribution
of oligonucleotide probes (green bars) in the commercially available
whole-genome Agilent SurePrint G3 Human CGH Microarray
8 × 60K. As evidenced in the figure, this platform has just one probe
overlapping PINK1 exon 5, proving low-resolution coverage. d
Distribution of oligonucleotide probes (blue bars) in the whole-genome
Agilent SurePrint G3 Human CGHMicroarray 1 × 1M slide format. The
highest-resolution 1 × 1M array CGH reveals the PINK1 genetic region
with a greater number of oligonucleotide probes; however, it is five times
more expensive per sample than the Agilent 8 × 60K slide format and
leaves uncovered some exonic traits (for example, exon 1 or 2). e
Distribution of oligonucleotide probes (red bars) in the entire exonic
regions of the PINK1 gene in the customized NeuroArray design. The
NeuroArray design allows high-density probe enrichment in the entire
exonic regions of PINK1, enabling a focused evaluation of structural
imbalances at a single-exon resolution with costs comparable to an
8 × 60K slide format. (Colour figure online)
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but was not able to detect the exon 4 deletion because during
the phase of array design, this exon skipped the optimum
parameters for probe coverage. The total concordance with
the MLPA test was 91 %. Despite this limit, the one-probe
analysis was essential to detect the exon 5 PARK2 deletion,
which otherwise would not have been properly outlined using
the analysis of three consecutive probes. However, this ap-
proach may result in a great number of false positives.
Therefore, it is advisable to use it as a validation strategy for
previously known exonic imbalances, i.e. next generation se-
quencing (NGS)-targeted panels, or to investigate copy num-
ber changes in a small set of strongly causative genes.
Discussion
In recent years, several studies have highlighted the key role
of CNVs in the development of hereditable or sporadic neu-
rological diseases, including PD [14–16]. Many gene-dosage
anomalies have been previously mapped in PD patients, in-
cluding familiar genes (SNCA, PARK2, PINK1, PARK7,
ATP13A2) [48, 49], as well as several rare CNVs in candidate
regions [45]. The aCGH biotechnology currently represents a
useful tool for the detection of unbalanced chromosomal
changes across the human genome, and its applications to
screen common benign and rare pathogenetic CNVs are ex-
tensively growing [19–23]. The classical methodologic ap-
proaches are a gold-standard test when applied to monogenic
disorders, but when applied to multigenic complex patholo-
gies (such as PD), they require higher equipment costs, time,
steps and personnel [50]. Conversely, targeted aCGH is rapid,
relatively inexpensive, highly sensitive and an accurate meth-
od to simultaneously detect single- and multi-exon CNVs in
numerous genes on a unique common platform. For this rea-
son, several whole-genome and exon-targeted aCGH plat-
forms have already been implemented in human diseases
[19–24], and their utility has been demonstrated in patients
with various clinical complex phenotypes [51–53].
In this study, we have designed and validated a targeted
exon-centric aCGH platform (NeuroArray) as a molecular
testing tool to simultaneously screen CNV imbalances in a
large set of clinically relevant genes for PD and other complex
neurological diseases. This customized design offers some
considerable advantages: it allows an exon-focused evaluation
of structural imbalances in clinically relevant regions at a
higher resolution than whole-genome commercially available
platforms and lowers the costs of an Bexon by exon^ analysis
through PCR-based approaches, simultaneously providing an
extensive window of further potentially involved genetic
alterations.
In addition to the customized design, we also applied sev-
eral approaches for data analysis. The first interesting result
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Fig. 3 A representative example of CNV detection involving PD-related
genes in a patient with early-onset PD. The NeuroArray platform detected
several CNVs in a female patient with early-onset PD and amild phenotype
(the reader is also referred to Table 2). a Visualization of the NSF deletion
detected by NeuroArray as shown by CytoGenomics software. The left
panel shows the entire chromosome 1, while the right panel is a zoom-in
of the deleted region (indicated by the red area). Red and blue dots
represent the log2 ratios for the relative hybridization intensities of each
spotted probe. b Visualization of the PARK7 amplification detected by
NeuroArray as shown by CytoGenomics software. The left panel shows
the entire chromosome 17, while the right panel is a zoom-in of the
amplified region (indicated by the blue area). For red and blue dots, see
a. Dots with an average log2 ratio of approximately +0.58 indicate a
heterozygous amplification. c Validation of both CNVs of NSF and
PARK7 by qPCR. Relative gene dosage levels of NSF and PARK7 genes
are based on delta Ct calculation. Ct values of both genes were normalized
to the Ct value of a normal diploid gene. The relative level of each gene of
interest is presented as the mean of 2−ΔΔCt, as described in the BMethods^
section. Error bars indicate standard deviations from the mean. (Colour
figure online)
Fig. 4 Detection of intragenic PARK2 deletion (exon 5) in a patient with
autosomal juvenile Parkinson’s disease. Heterozygous deletion of exon 5 of
the PARK2 gene detected by NeuroArray in a patient with juvenile
Parkinson’s disease (PD) and previously revealed by an MLPA assay. a
NeuroArray aCGH data visualization and analysis as shown by
CytoGenomics software. The red area represents the deleted region. The
top of the panel shows the size of the deletion and the chromosomal locus.
Red and blue dots represent the log2 ratios for the relative hybridization
intensities of each spotted probe. The dots with an average log2 ratio around
−1 indicate a heterozygous deletion. b The panel displays the PARK2 gene as
annotated in the UCSC Genome Browser Feb. 2009 GRCh37/hg19
(https://genome-euro.ucsc.edu). Blue boxes represent exons and are
numbered consecutively, whereas grey arrows are the intronic regions.
(Colour figure online)
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ADM-2 algorithms for CNV calling aberrations in order to
reduce the number of false positives and to bring out relevant
CNVs that otherwise would have been lost. We have also
employed a one-probe analysis to reveal small imbalances at
the single-exon level. Although this approach has the potential
to detect crucial genetic variations ignored by multi-probe
analysis, it largely increases the quantity of false-positive
probe signals. Therefore, the single-probe analysis would be
a useful validation strategy for NGS experiments or to inves-
tigate exon copy number changes in a smaller set of causative
genes (as we performed with the script in the R-platform).
The use of dedicated high-throughput genotyping plat-
forms like our NeuroArray could offer new opportunities for
the PD genomic research field, mainly for familiar PD cases
with an incomplete molecular diagnosis or sporadic cases
without any detected genetic anomalies. The large-scale
screening of genes that are involved in nervous system dys-
functions could allow for differential diagnosis with other
common neurological disorders, refine the genotype-
phenotype correlations and explore the potential genetic over-
lapping signatures among different neurological conditions
[54]. Specifically, the PD panel shares a good number of genes
with other neurological diseases (Fig. 1). Given the existence
of PD patients with combined clinical and pathological fea-
tures [55–57], this strategy could be useful to investigate com-
mon genetic anomalies underlying very complex phenotypes.
Similarly to other aCGH-based technology, NeuroArray
has some limitations, such as the inability to detect mosaicism
poorly represented, balanced structural chromosomal abnor-
malities, nucleotide repeat expansions (e.g. in C9orf72 or
ATXN2 genes) and mutations included in regions not covered
by probes. To overcome some of these limits and reduce the
number of false-positive signals, we are developing a second
version of the NeuroArray design with the aim of improving
probe coverage in non-targeted genomic regions, including
(where necessary) the intronic flanking regions and the alter-
natively spliced cassette exons of relevant PD genes [58–60].
Conclusions
Our NeuroArray platform represents a powerful and reliable
tool for the analysis of genomic imbalances associated with
PD and other neurological diseases. Compared to PCR-based
approaches applied to multigene analysis or to whole-genome
commercially available CGH arrays, it provides a focused
higher resolution at a lower cost, enabling a more detailed
analysis of clinically relevant exonic regions and offering a
better cost/benefit ratio. In future years, the use of this plat-
form may offer new insights into the investigation of new
genetic molecular anomalies contributing to PD, as well as a
more precise definition of genotype-phenotype relationships.
It may also offer novel clues in the elucidation of potential
genetic overlapping among different neurological conditions.
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